TBThomas Brevig

Thomas Brevig

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thomas Brevig has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Jens Zimmer

    Department of Anatomy and Neurobiology, University of Southern Denmark, DK-5000 Odense C, Denmark; Department of Clinical Immunology, Odense University Hospital, DK-5000 Odense C, Denmark; and Division of Clinical Immunology, Karolinska Institute, Huddinge University Hospital, S-141 86 Huddinge, Sweden

    3 shared publications
  • Tom Kristensen

    Department of Anatomy and Neurobiology, University of Southern Denmark, DK-5000 Odense C, Denmark; Department of Clinical Immunology, Odense University Hospital, DK-5000 Odense C, Denmark; and Division of Clinical Immunology, Karolinska Institute, Huddinge University Hospital, S-141 86 Huddinge, Sweden

    3 shared publications
  • Morten Meyer

    Department of Anatomy and Neurobiology, University of Southern Denmark, DK-5000 Odense C, Denmark; Department of Clinical Immunology, Odense University Hospital, DK-5000 Odense C, Denmark; and Division of Clinical Immunology, Karolinska Institute, Huddinge University Hospital, S-141 86 Huddinge, Sweden

    2 shared publications
  • Jan Holgersson

    Department of Anatomy and Neurobiology, University of Southern Denmark, DK-5000 Odense C, Denmark; Department of Clinical Immunology, Odense University Hospital, DK-5000 Odense C, Denmark; and Division of Clinical Immunology, Karolinska Institute, Huddinge University Hospital, S-141 86 Huddinge, Sweden

    1 shared publication

Latest Publications

  • XENOTRANSPLANTATION FOR BRAIN REPAIR

    by Thomas Brevig, Morten Meyer, Tom Kristensen, Jens Zimmer, Jan Holgersson

    Background. Transplantation of embryonic neural tissue is a potential treatment for Parkinson’s disease. Because human donor material is in short supply, porcine xenografts are considered a useful alternative. Current immunosuppressive therapies fail, however, to protect intracerebral neural xenografts from host CD4 T lymphocytes. To reduce the immunogenicity of porcine donor tissue, we attempted to remove microglial cells with antibodies against the α-galactosyl epitope (Galα1,3Galβ1,4GlcNAc-R), or anti-Gal, and complement, and studied whether this pretreatment can reduce direct and indirect T-cell responses to the tissue. Methods. Brain tissue from 27-day-old pig embryos was dissociated and treated with human anti-Gal and rabbit complement. The microglial content was analyzed by flow cytometry. [3H]thymidine incorporation in cocultures of the brain cells and purified human CD4 T cells was used to determine direct T-cell responses. Indirect T-cell responses were studied by grafting pretreated and control-pretreated (no anti-Gal) nigral tissue into the lesioned striatum of immunocompetent rats with 6-hydroxydopamine-induced hemiparkinsonism. Amphetamine-induced circling behavior was used to measure graft function. Results. Anti-Gal and complement reduced the microglial content to 11–24% of control and abolished the ability of the brain cells to induce human CD4 T-cell proliferation. Pretreated nigral tissue reduced hemiparkinsonism by more than 50% in five of eight rats at some point during the 10-week follow-up. Rats receiving control-pretreated nigral tissue did not display this degree of improvement. Conclusions. Pretreatment with anti-Gal and complement can reduce the immunogenicity of porcine neural tissue, and might, therefore, be a valuable alternative or supplement to immunosuppression in neural xenotransplantation.


  • Open Access

    Neural Xenotransplantation: Pretreatment of Porcine Embryonic Nigral Tissue with Anti-Gal Antibodies and Complement is not Toxic for the Dopaminergic Neurons

    by Thomas Brevig, Morten Meyer, Tom Kristensen, Jens Zimmer

    The immunogenicity of porcine tissue is a major obstacle to its use as donor material in xenotransplantation for neurodegenerative diseases. We are currently evaluating a novel strategy for reducing the immunogenicity, in which the α-galactosyl epitope (Galα1,3Galß1,4GlcNAc-R) is used as a target for antibody- and complement-mediated removal of microglia. In the present study, our aim was to determine whether a pretreatment with antibodies against the α-galactosyl epitope (anti-Gal) and complement would lyse or other-wise damage dopaminergic neurons in porcine embryonic ventral mesencephalon (VM), the donor tissue for treatment of Parkinson's disease by xenotransplantation. Cell suspensions prepared from VM tissue from 27-day-old pig embryos were incubated with anti-Gal, purified from normal human serum by affinity chromatography, or medium only (control), and subsequently with rabbit complement. After these pretreatments, the cell suspensions were transplanted into the right striatum of 14 adult rats (two groups of 7 animals). The animals were sacrificed 20 days after transplantation, the brains were processed for histology, and the sections were stained for Nissl substance, porcine neurofilament, tyrosine hydroxylase, and rat CD45 to determine graft volume, presence of porcine neurons, content of dopaminergic cells, and leukocyte infiltration, respectively. The VM tissue pretreated with anti-Gal and complement gave rise to dopaminergic grafts that were indistinguishable from those derived from VM tissue given the control pretreatment. In 5 of the 14 animals, the grafts were infiltrated by host leukocytes, but in two of these recipients, the infiltration was only minimal. We conclude that anti-Gal and complement can be applied to porcine embryonic VM tissue without damaging the dopaminergic neurons and their precursors.